SEGANSERIN

Details

Stereochemistry	ACHIRAL
Molecular Formula	C29H27F2N3O
Molecular Weight	471.541
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=C(CCN2CCC(CC2)=C(C3=CC=C(F)C=C3)C4=CC=C(F)C=C4)C(=O)N5C=CC=CC5=N1

InChI

InChIKey=ZGUPMFYFHHSNFK-UHFFFAOYSA-N

InChI=1S/C29H27F2N3O/c1-20-26(29(35)34-16-3-2-4-27(34)32-20)15-19-33-17-13-23(14-18-33)28(21-5-9-24(30)10-6-21)22-7-11-25(31)12-8-22/h2-12,16H,13-15,17-19H2,1H3

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8853256

Seganserin was developed as a specific serotonin 5HT2 receptor antagonist. It was tested neuropharmacologically in thioacetamide-induced acute liver failure in rats. Obtained results have shown that seganserin had no effect in encephalopathic rats.

Approval Year

PubMed

Title	Date	PubMed
Characterization of flufylline, fluprofylline, ritanserin, butanserin and R 56413 with respect to in-vivo alpha 1-,alpha 2- and 5-HT2-receptor antagonism and in-vitro affinity for alpha 1-,alpha 2- and 5-HT2-receptors: comparison with ketanserin.	1986 May	2872314
Effects of seganserin, a 5-HT2 antagonist, and temazepam on human sleep stages and EEG power spectra.	1989 Nov 21	2576000
Modulation of hepatic encephalopathy in rats with thioacetamide-induced acute liver failure by serotonin antagonists.	1996 Jul	8853256
Effect of 5-HT1A and 5-HT2A/2C receptor modulation on neuroleptic-induced vacuous chewing movements.	2001 Sep 28	11779040

Patents

Name

Type

Language

SEGANSERIN

Official Name

English

seganserin [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C66885